Your browser doesn't support javascript.
loading
A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab-paclitaxel.
Patel, Shetal A; Singer, Bart; Shen, Colette; Zanation, Adam M; Yarbrough, Wendell G; Weiss, Jared.
Afiliación
  • Patel SA; Division of Oncology Lineberger Comprehensive Cancer Center at the University of North Carolina Chapel Hill North Carolina USA.
  • Singer B; Department of Pathology and Laboratory Medicine University of North Carolina Chapel Hill North Carolina USA.
  • Shen C; Department of Radiation Oncology Lineberger Comprehensive Cancer Center at the University of North Carolina Chapel Hill North Carolina USA.
  • Zanation AM; Department of Otolaryngology/Head and Neck Surgery Lineberger Comprehensive Cancer Center at the University of North Carolina Chapel Hill North Carolina USA.
  • Yarbrough WG; Department of Otolaryngology/Head and Neck Surgery Lineberger Comprehensive Cancer Center at the University of North Carolina Chapel Hill North Carolina USA.
  • Weiss J; Division of Oncology Lineberger Comprehensive Cancer Center at the University of North Carolina Chapel Hill North Carolina USA.
Clin Case Rep ; 9(8): e04616, 2021 Aug.
Article en En | MEDLINE | ID: mdl-34429997
ABSTRACT

BACKGROUND:

NUT carcinoma is an aggressive malignancy characterized by translocations in the NUTM1 gene. There are currently no consensus treatment recommendations for NUT carcinomas.

METHODS:

Here, we describe the case of a previously healthy male diagnosed with NUT carcinoma after presenting with sinus pressure, found to have a sinonasal mass and distant metastatic disease in the lungs. While pathologic evaluation and immunohistochemistry were consistent with NUT carcinoma, initial genomic profiling did not demonstrate a NUTM1 translocation.

RESULTS:

Whole transcriptomic RNA sequencing of the tumor revealed a YAP1-NUTM1 fusion. Based on an in vitro drug sensitivity screen, the patient was treated with gemcitabine and nab-paclitaxel, achieving a partial response that persisted for 9 months.

CONCLUSIONS:

Unbiased transcriptomic sequencing may identify previously uncharacterized NUTM1 fusion partners. Gemcitabine and nab-paclitaxel is a well-tolerated combination chemotherapy regimen and could offer a novel treatment approach for NUT carcinoma.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Clin Case Rep Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Clin Case Rep Año: 2021 Tipo del documento: Article